- Home
- BCAB vs PLX Comparison
BCAB vs PLX Comparison
Compare BCAB & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- PLX
- Stock Information
- Founded
- BCAB 2007
- PLX 1993
- Country
- BCAB United States
- PLX Israel
- Employees
- BCAB N/A
- PLX N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAB Health Care
- PLX Health Care
- Exchange
- BCAB Nasdaq
- PLX Nasdaq
- Market Cap
- BCAB 91.4M
- PLX 69.9M
- IPO Year
- BCAB 2020
- PLX 1998
- Fundamental
- Price
- BCAB $1.69
- PLX $1.06
- Analyst Decision
- BCAB Strong Buy
- PLX Strong Buy
- Analyst Count
- BCAB 3
- PLX 1
- Target Price
- BCAB $8.67
- PLX $10.00
- AVG Volume (30 Days)
- BCAB 1.1M
- PLX 182.9K
- Earning Date
- BCAB 08-08-2024
- PLX 11-04-2024
- Dividend Yield
- BCAB N/A
- PLX N/A
- EPS Growth
- BCAB N/A
- PLX N/A
- EPS
- BCAB N/A
- PLX N/A
- Revenue
- BCAB N/A
- PLX $38,053,000.00
- Revenue This Year
- BCAB N/A
- PLX N/A
- Revenue Next Year
- BCAB N/A
- PLX $92.43
- P/E Ratio
- BCAB N/A
- PLX N/A
- Revenue Growth
- BCAB N/A
- PLX N/A
- 52 Week Low
- BCAB $1.14
- PLX $0.82
- 52 Week High
- BCAB $4.02
- PLX $1.90
- Technical
- Relative Strength Index (RSI)
- BCAB 51.76
- PLX 54.88
- Support Level
- BCAB $1.72
- PLX $0.98
- Resistance Level
- BCAB $1.92
- PLX $1.05
- Average True Range (ATR)
- BCAB 0.13
- PLX 0.05
- MACD
- BCAB -0.01
- PLX 0.01
- Stochastic Oscillator
- BCAB 33.92
- PLX 71.43
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.